Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667511 · ClinicalTrials.gov registry record · NA
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
A NA study of End Stage Renal Disease and Kidney Failure, Chronic, sponsored by NxStage Medical.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 9
- Study locations
NCT00667511: Completed NA study of End Stage Renal Disease and Kidney Failure, Chronic, sponsored by NxStage Medical.
NCT00667511 is a NA study of End Stage Renal Disease and Kidney Failure, Chronic that has completed, run by NxStage Medical. The registered enrollment target is 58 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667511, a NA study of End Stage Renal Disease and Kidney Failure, Chronic, has completed, sponsored by NxStage Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine whether or not nocturnal hemodialysis is equivalent to short daily hemodialysis on a per treatment basis, using the NxStage System One in the home setting.
Primary Outcome
The primary efficacy endpoint for the study was the ability to deliver the clinically prescribed amount of therapy, defined by attainment of a delivered volume that was at least 90% of the prescribed volume (10% difference in success rate is the upper boundary of the 95% confidence interval).
Conditions Studied
Interventions
- DEVICE NxStage System One
Study Locations (9)
California
- Satellite Healthcare/Wellbound - San Jose
Illinois
- Circle Medical Management - Chicago
Indiana
- Indiana University Dialysis Center - Indianapolis
Kansas
- Kansas Nephrology Research Institute, LLC - Wichita
Missouri
- Barnes Jewish Dialysis Center - St Louis
Nebraska
- Dialysis Center of Lincoln - Lincoln
New York
- Rubin Dialysis - Saratoga Springs
Texas
- DaVita Grapevine at Home - Grapevine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-05 |
| Phase | NA |
What the finished NCT00667511 record still lists
NCT00667511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which NxStage System One is the first listed.
NCT00667511 lists 9 locations in 9 states (California, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT00667511 about?
NCT00667511 is a clinical study titled "Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™". The purpose of this study is to determine whether or not nocturnal hemodialysis is equivalent to short daily hemodialysis on a per treatment basis, using the NxStage System One in the home setting.
What is the current status of trial NCT00667511?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2008-04. Estimated completion is 2014-05.
What conditions does trial NCT00667511 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Failure, Chronic.
What interventions are being tested in trial NCT00667511?
The interventions under investigation include: NxStage System One (DEVICE).
Who is sponsoring clinical trial NCT00667511?
This trial is sponsored by NxStage Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00667511 being conducted?
This trial has 9 study locations across California, Illinois, Indiana, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00667511's enrollment target sits among peer trials
58 49th of 86 higher than 37 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
RECRUITING · NA
-
CAPABLE Transplant
RECRUITING · NA
-
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia